Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Roche To Acquire Anadys

by Rick Mullin
October 24, 2011 | A version of this story appeared in Volume 89, Issue 43

To bolster its pipeline of hepatitis C virus (HCV) therapies, Roche has agreed to acquire Anadys Pharmaceuticals, a developer of small-molecule HCV treatments, for about $230 million. Anadys recently reported positive data on Phase IIb clinical trials of setrobuvir, the company’s most advanced drug candidate, in combination with PEGylated interferon and ribavirin. “Anadys’ compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance,” says Jean-Jacques Garaud, Roche’s global head of pharma research and early development. The Swiss firm’s current HCV portfolio includes blood tests and Pegasys, a once-a-week injection of PEGylated interferon. Earlier this year, Roche signed a nonexclusive pact with Merck & Co. under which it will promote Pegasys in combination with Merck’s newly approved Victrelis, a protease inhibitor for HCV. Vertex Pharmaceuticals also entered the HCV field recently with the protease inhibitor Incivek.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.